Hypermetabolic response to thermal injury

Overview

Severe thermal injury triggers a biphasic metabolic response: an initial ebb phase of reduced metabolism and tissue perfusion, followed by a prolonged flow phase of hypermetabolic rates and hyperdynamic circulation ^[1][2]. This flow phase is mediated by up to 50-fold elevations in plasma catecholamines, cortisol, and glucagon, producing whole-body catabolism, elevated resting energy expenditure, and multiorgan dysfunction ^[3]. The hypermetabolic response after major burns is among the most extreme and prolonged of any clinical condition, persisting for up to two years or longer and driving catabolism of muscle, bone, and adipose tissue that profoundly impairs rehabilitation and reintegration.

Pathophysiology

The hypermetabolic response is driven by a surge of catecholamines, cortisol, glucagon, and inflammatory cytokines that persists for months to years beyond wound closure ^[4][5]. This hormonal cascade produces characteristic metabolic derangements: supraphysiologic energy expenditure, skeletal muscle proteolysis, accelerated lipolysis, insulin resistance, and mitochondrial dysfunction ^[4]. These mediators are potential therapeutic targets for pharmacologic modulation of the hypermetabolic state ^[4][5]. At the cellular level, sustained catecholamine excess causes direct skeletal muscle injury through beta-adrenergic overstimulation, mitochondrial uncoupling, and calcium dysregulation, compounding the proteolysis driven by systemic inflammation ^[15][16].

Jeschke et al. conducted a landmark prospective study of 242 severely burned pediatric patients (mean burn size 56% TBSA) and demonstrated that all patients remained markedly hypermetabolic throughout acute hospitalization, with negative muscle protein net balance (-0.05 nmol/100 mL leg/min), loss of lean body mass (-4.1%), and reductions in bone mineral content (-3%) and bone mineral density (-2%) ^[6]. Burn size is a key determinant: patients with burns exceeding 80% TBSA had the highest resting energy expenditure, the greatest loss of lean body mass and bone mineral content, and the highest mortality ^[7]. Endogenous anabolic hormones including IGF-I, IGFBP-3, growth hormone, and insulin were drastically reduced by 3- to 5-fold for up to 40 days post-injury, with notable gender differences favoring higher anabolic hormone levels in females ^[8].

The metabolic response includes accelerated gluconeogenesis, glucose oxidation, and considerable futile cycling of carbohydrate intermediates, with glucose utilization capped at a beneficial threshold of 5-6 mg/kg/min ^[1].

Pharmacologic modulation

Beta-adrenergic blockade with propranolol is the most extensively studied pharmacologic intervention. Pereira et al. reviewed the evidence demonstrating that propranolol reduces the catabolic effects of sustained catecholamine elevations by increasing protein synthesis while peripheral lipolysis declines ^[9]. The mechanism appears to involve enhanced net protein synthesis in the face of persistent protein breakdown ^[9][10]. A pharmacokinetic study by Guillory et al. in 26 severely burned adults (burns covering 30% or more TBSA) found that Q6 dosing (every 6 hours) was the most effective strategy for maintaining reduced heart rate throughout dosing periods, with significantly higher plasma propranolol concentrations than Q8 dosing (P = 0.02) ^[11]. A systematic review by Nunez-Villaveira et al. of 15 randomized trials confirmed that propranolol at 4-6 mg/kg/day reduces supraphysiological thermogenesis, cardiac work, resting energy expenditure, and peripheral lipolysis, providing multicenter confirmation of the single-institution findings ^[17].

Oxandrolone, a synthetic testosterone analog, was studied in a large prospective randomized trial by Jeschke et al. involving 235 pediatric patients with burns exceeding 40% TBSA. Oxandrolone-treated patients had preserved lean body mass (+9% vs. -8% in controls, P < 0.05) and significantly shorter ICU stays (0.48 vs. 0.56 days per percent burn, P < 0.05). Serum prealbumin, total protein, and testosterone were increased without adverse effects on liver function or inflammatory markers ^[12]. (Note: Oxandrolone has been removed from the US market by the FDA and should be considered historical evidence. It is not currently available as standard therapy; clinical use would require accessing the drug through alternative regulatory pathways.)

Non-pharmacologic strategies

Herndon and Tompkins identified the most effective anabolic strategies as: early excision and grafting, prompt sepsis treatment, maintenance of environmental temperature at 30-32 degrees C, continuous high-carbohydrate high-protein enteral feeding, and early institution of vigorous resistive exercise programs ^[13]. Hart et al. demonstrated in a cohort analytic study of 46 burned children that early excision combined with aggressive enteral feeding markedly attenuated muscle protein catabolism and reduced wound colonization and sepsis rates, even though energy expenditure itself was not decreased ^[14]. Williams and Herndon emphasized that modulation of the hypermetabolic response through combined pharmacologic and non-pharmacologic approaches has markedly decreased morbidity over the past two decades ^[3].

Controversies and Evidence Gaps

Optimal propranolol dosing remains debated. While Q6 dosing maintains the most consistent heart rate reduction, once-daily (Q24) formulations showed similar efficacy in a small study, and no large multicenter trial has compared regimens head-to-head. Oxandrolone demonstrated significant benefits in pediatric populations but has been removed from the US market, limiting its clinical applicability; its use in adult women and its long-term safety profile remain insufficiently studied. Recombinant human growth hormone, while effective as an anabolic agent, carries concerns about hyperglycemia and increased mortality that have limited its adoption. The duration of pharmacologic therapy is uncertain, with some authors advocating treatment for 2 to 3 years post-injury, but compliance and cost-effectiveness data are lacking. Most landmark studies come from a single institution (Shriners/UTMB Galveston), though systematic reviews pooling data from multiple centers have corroborated the core findings ^[17].

References

[1] Tredget EE et al. (1992). The metabolic effects of thermal injury. PMID: 1290269 [2] Lee JO et al. (2003). Modulation of the post-burn hypermetabolic state. PMID: 12968447 [3] Williams FN et al. (2017). Metabolic and Endocrine Considerations After Burn Injury. PMID: 28576243 [4] Auger C et al. (2017). The biochemical alterations underlying post-burn hypermetabolism. PMID: 28219767 [5] Sommerhalder C et al. (2020). Current problems in burn hypermetabolism. PMID: 32033707 [6] Jeschke MG et al. (2008). Pathophysiologic response to severe burn injury. PMID: 18791359 [7] Jeschke MG et al. (2007). Burn size determines the inflammatory and hypermetabolic response. PMID: 17716366 [8] Jeschke MG et al. (2005). Endogenous anabolic hormones and hypermetabolism: effect of trauma and gender differences. PMID: 15849511 [9] Pereira CT et al. (2007). Beta-blockade in burns. PMID: 17380798 [10] Pereira CT et al. (2005). Altering metabolism. PMID: 15879740 [11] Guillory AN et al. (2017). Propranolol kinetics in plasma from severely burned adults. PMID: 28645713 [12] Jeschke MG et al. (2007). The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. PMID: 17717439 [13] Herndon DN et al. (2004). Support of the metabolic response to burn injury. PMID: 15183630 [14] Hart DW et al. (2003). Effects of early excision and aggressive enteral feeding on hypermetabolism, catabolism, and sepsis after severe burn. PMID: 12707540 [15] Knuth CM et al. (2021). Burn-induced hypermetabolism and skeletal muscle dysfunction. Am J Physiol Cell Physiol. PMID: 33909503 [16] Blears E et al. (2021). The impact of catecholamines on skeletal muscle following massive burns: Friend or foe? Burns. PMID: 33568281 [17] Nunez-Villaveira T et al. (2015). Systematic review of the effect of propranolol on hypermetabolism in burn injuries. Med Intensiva. PMID: 25305241